Related Experiment Video

Updated: Aug 3, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different

S S Göksu1, H Bozcuk, L Koral

  • 1Department of Medical Oncology, Kayseri State Hospital of Research and Education, Kayseri, Turkey.

Indian Journal of Cancer
|March 11, 2016
PubMed
Abstract

Insights

Lapatinib efficacy in metastatic breast cancer depends on histologic subtype and metastasis site. Clinicians should consider these factors when selecting patients for lapatinib treatment after trastuzumab progression.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Trastuzumab is a key treatment for HER-2+ breast cancer, but resistance develops.
  • Lapatinib is an alternative treatment option after trastuzumab failure, but patient selection criteria are unclear.

Purpose of the Study:

  • To identify factors predicting lapatinib efficacy in metastatic breast cancer patients.
  • To guide clinical decisions for lapatinib use post-trastuzumab treatment.

Main Methods:

  • Retrospective analysis of 94 metastatic breast carcinoma patients treated with lapatinib.
  • Data collected included pathology, treatment history, metastatic sites, and laboratory results.

Main Results:

  • Progression-free survival (PFS) with lapatinib was 9.1 months.
  • Non-invasive ductal carcinoma subtypes and liver metastasis were associated with shorter PFS.
  • Overall survival was 22.1 months; brain metastasis and non-invasive ductal carcinoma subtypes predicted worse prognosis.

Conclusions:

  • Histologic subtype and metastatic site are crucial factors in predicting lapatinib efficacy.
  • Consider non-invasive ductal carcinoma and liver/brain metastases when prescribing lapatinib.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

626

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...